ASCO Posters Feature Data on MT-3724 and Ifosfamide
AUSTIN, Texas, June 04, 2018 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq:MTEM), a clinical degree biopharmaceutical organization centered at the discovery and development of Engineered Toxin Bodies, a brand new magnificence of focused biologic treatment plans that own specific mechanisms of movement in oncology, these days announced that statistics on of its pipeline programs had been supplied at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, held June 1-five in Chicago, Illinois.
Poster Title: Safety and Efficacy of Anti-CD20 Immunotoxin MT-3724 in Relapsed/Refractory B-cell non-Hodgkin Lymphoma (NHL) in a Phase 1 Study
First Author: Paul A. Hamlin, MD, Memorial Sloan Kettering Cancer Center
The poster summarized meantime outcomes from a Phase I and Phase Ib extension observe of B-cell non-Hodgkin’s lymphoma (NHL) patients dealt with MT-3724 who had formerly relapsed after anti-CD20 Mab and chemotherapy. Consistent with the mechanism of movement, enzymatic ribosome inactivation, the satisfactory pastime is determined in closely pretreated sufferers with relapsed or refractory diffuse big B-cell lymphoma (DLBCL) (N=18; median of five earlier healing procedures).
Patients with excessive circulating stages of rituximab (RTX) at have a look at entry confirmed negative response to MT-3724 because of aggressive inhibition and blockading of CD20 receptor via RTX. As a result, the continued Phase Ib extension and future studies of MT-3724 will join handiest patients with low levels of RTX.
The preliminary goal reaction fee in DLBCL patients with low serum Rituxan tiers at study access (N=10) changed into 30%, with an ailment control rate of 70%, including two solid ailment sufferers that had tumor discounts of forty-seven % and 49%. The ongoing Phase Ib study will further symbolize the reaction fee and period of reaction.
MT-3724 changed into typically properly tolerated and a redefined most tolerated dose (MTD) of 50 mcg/kg with a most of 6 mg consistent with dose became applied based on revel in with sufferers with high body weight who acquired a high total dose at 75mcg/kg. Enrollment inside the have a look at has currently resumed after approval of the brand new MTD.
In addition to this ongoing Phase Ib extension, Molecular Templates expects to start Phase II combos research in 2H18 and a Phase II monotherapy observe at the quiet of the 12 months that may be pivotal.
Poster Title: Unexpected Pharmacokinetics of Evofosfamide Observed in Phase III MAESTRO Study
First Author: Jack P. Higgins, Ph.D., Molecular Templates, Inc.
This poster compares the pharmacokinetic (PK) profile of ifosfamide from the Phase II (“404” observe) and Phase III (“MAESTRO”) trials finished in sufferers with superior pancreatic cancer. The Phase II (“404”) examine of ifosfamide in pancreatic most cancers (N=214) showed promising reaction fees, progression-loose survival, and ordinary survival. MAESTRO, a Phase III look at within the identical patient population (N=693) failed to replicate the scientific gain seen in Phase II (“404”) have a look at. A new ethanol-based formation turned into delivered before the initiation of MAESTRO and the drug exposure become drastically lower than the exposure inside the Phase II (“404”) study on the identical dose. In the Japanese MAESTRO patients who acquired ifosfamide (N=59), considerably higher drug publicity was found with correspondingly better clinical consequences versus patients in the exam from the rest of the world. We surmise that the system exchange may have adversely affected drug exposure and can have triggered the reduced medical gain found in MAESTRO.
Ifosfamide (in the present day ethanol-based method) at higher doses is presently being evaluated in a Phase I have a look at, in mixture with ipilimumab, in an try to replicate the publicity visible with the previous formulation in Phase II (“404”) look at. Molecular Templates plans to explore capability partnership possibilities for further development of ifosfamide.
About Molecular Templates
Molecular Templates is focused on the discovery, development, and commercialization of subsequent-generation immunotoxins called Engineered Toxin Bodies (ETB) for the remedy of cancers and other serious sicknesses. For extra records, please visit Molecular Templates’
This press launch includes forward-looking statements for functions of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any rationale or responsibility to update those ahead-looking statements and claims the safety of the Act’s Safe Harbor for ahead-searching statements. All statements, other than statements of historical records, covered in this press launch regarding the method, destiny operations, future economic role, destiny revenue, projected costs, potentialities, plans, and goals of management are forward-looking statements. In addition, whilst or if used in this press release, the words “might also,” “ought to,” “ought to,” “assume,” “trust,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their versions, as they relate to Molecular Templates may additionally perceive forward-looking statements. Examples of such statements include, but aren’t confined to, statements referring to the development of the Company’s lead software, MT-3724; the predicted timing of filing numerous IND applications and beginning studies; and the Company’s notion that its proprietary biologic drug platform generation, or ETBs, provides for a differentiated mechanism of motion that may deal with a number of the restrictions associated with currently available most cancers therapeutics.
Forward-looking statements are not ensured of destiny overall performance and contain dangers and uncertainties. Actual events or outcomes might also range materially from those mentioned inside the ahead-looking statements because of different factors including, however now not confined to, the uncertainties inherent in the preclinical and scientific development system; whether or not the Company’s cash sources may be sufficient to fund its persevering with operations for the intervals and/or trials anticipated; the capacity of the Company to shield its intellectual assets rights; and legislative, regulatory, political and financial developments, as well as those dangers recognized underneath the heading “Risk Factors” inside the Company’s filings with the SEC. Any forward-looking statements contained on this press release speak best as of the date hereof, and the Company, in particular, disclaims any duty to update any ahead-searching assertion, whether or not due to new records, future occasions or otherwise.